RGD Reference Report - Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer.

Authors: Olsen, RR  Zetter, BR 
Citation: Olsen RR and Zetter BR, Mol Cancer Res. 2011 Oct;9(10):1285-93. doi: 10.1158/1541-7786.MCR-11-0178. Epub 2011 Aug 17.
RGD ID: 7244195
Pubmed: PMID:21849468   (View Abstract at PubMed)
PMCID: PMC3196680   (View Article at PubMed Central)
DOI: DOI:10.1158/1541-7786.MCR-11-0178   (Journal Full-text)

Antizyme and its endogenous antizyme inhibitor have recently emerged as prominent regulators of cell growth, transformation, centrosome duplication, and tumorigenesis. Antizyme was originally isolated as a negative modulator of the enzyme ornithine decarboxylase (ODC), an essential component of the polyamine biosynthetic pathway. Antizyme binds ODC and facilitates proteasomal ODC degradation. Antizyme also facilitates degradation of a set of cell cycle regulatory proteins, including cyclin D1, Smad1, and Aurora A kinase, as well as Mps1, a protein that regulates centrosome duplication. Antizyme has been reported to function as a tumor suppressor and to negatively regulate tumor cell proliferation and transformation. Antizyme inhibitor binds to antizyme and suppresses its known functions, leading to increased polyamine synthesis, increased cell proliferation, and increased transformation and tumorigenesis. Gene array studies show antizyme inhibitor to be amplified in cancers of the ovary, breast, and prostate. In this review, we summarize the current literature on the role of antizyme and antizyme inhibitor in cancer, discuss how the ratio of antizyme to antizyme inhibitor can influence tumor growth, and suggest strategies to target this axis for tumor prevention and treatment.

Molecular Pathway Annotations    Click to see Annotation Detail View

RGD Manual Annotations

Objects Annotated

Genes (Rattus norvegicus)
Azin1  (antizyme inhibitor 1)
Oaz1  (ornithine decarboxylase antizyme 1)
Oaz2  (ornithine decarboxylase antizyme 2)
Oaz3  (ornithine decarboxylase antizyme 3)

Genes (Mus musculus)
Azin1  (antizyme inhibitor 1)
Oaz1  (ornithine decarboxylase antizyme 1)
Oaz2  (ornithine decarboxylase antizyme 2)
Oaz3  (ornithine decarboxylase antizyme 3)

Genes (Homo sapiens)
AZIN1  (antizyme inhibitor 1)
OAZ1  (ornithine decarboxylase antizyme 1)
OAZ2  (ornithine decarboxylase antizyme 2)
OAZ3  (ornithine decarboxylase antizyme 3)


Additional Information